abrdn plc Takes Position in G1 Therapeutics, Inc. (NASDAQ:GTHX)

abrdn plc acquired a new position in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 423,869 shares of the company's stock, valued at approximately $1,293,000. abrdn plc owned approximately 0.82% of G1 Therapeutics at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Curi Wealth Management LLC increased its holdings in shares of G1 Therapeutics by 17.8% in the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company's stock valued at $102,000 after purchasing an additional 10,700 shares in the last quarter. Creative Financial Designs Inc. ADV increased its holdings in shares of G1 Therapeutics by 98.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company's stock valued at $108,000 after purchasing an additional 17,475 shares in the last quarter. Algert Global LLC acquired a new stake in shares of G1 Therapeutics in the third quarter valued at approximately $98,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company's stock valued at $294,000 after purchasing an additional 82,879 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of G1 Therapeutics in the third quarter valued at approximately $189,000. Institutional investors and hedge funds own 24.21% of the company's stock.

Insider Transactions at G1 Therapeutics

In other news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares of the company's stock, valued at $785,113.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.23% of the company's stock.

G1 Therapeutics Trading Up 1.3 %

GTHX stock traded up $0.05 during midday trading on Tuesday, reaching $3.77. The company's stock had a trading volume of 528,642 shares, compared to its average volume of 1,264,326. G1 Therapeutics, Inc. has a 52 week low of $1.08 and a 52 week high of $5.00. The stock has a market cap of $197.21 million, a PE ratio of -3.97 and a beta of 1.73. The company has a quick ratio of 3.45, a current ratio of 3.87 and a debt-to-equity ratio of 1.46. The business's 50-day simple moving average is $3.81 and its 200-day simple moving average is $3.04.

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $14.87 million for the quarter, compared to analysts' expectations of $12.83 million. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. During the same period last year, the firm posted ($0.73) earnings per share. As a group, sell-side analysts expect that G1 Therapeutics, Inc. will post -0.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GTHX shares. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price objective (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research note on Friday, April 12th.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.